PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

Ian J Majewski, Lorenza Mittempergher, Nadia M Davidson, Astrid Bosma, Stefan M Willems, Hugo M Horlings, Iris de Rink, Liliana Greger, Gerrit KJ Hooijer, Dennis Peters, Petra M Nederlof, Ingrid Hofland, Jeroen de Jong, Jelle Wesseling, Roelof JC Kluin, Wim Brugman, Ron Kerkhoven, Frank Nieboer, Paul Roepman, Annegien Broeks, Thomas R Muley, Jacek Jassem, Jacek Niklinski, Nico van Zandwijk, Alvis Brazma, Alicia Oshlack, Michel van den Heuvel, René Bernards, Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. The Journal of Pathology. ,vol. 230, pp. 270- 276 ,(2013) , 10.1002/PATH.4209

Dejan Juric, Ian Krop, Ramesh K. Ramanathan, Jim Xiao, Sandra Sanabria, Timothy R. Wilson, YounJeong Choi, Hema Parmar, Jerry Hsu, Jose Baselga, Daniel D. Von Hoff, Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. Cancer Research. ,vol. 73, ,(2013) , 10.1158/1538-7445.AM2013-LB-64

J Baselga, J Cortés, SA Im, E Clark, A Kiermaier, G Ross, SM Swain, None, Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) Cancer Research. ,vol. 72, ,(2012) , 10.1158/0008-5472.SABCS12-S5-1

Katrien Berns, Hugo M. Horlings, Bryan T. Hennessy, Mandy Madiredjo, E. Marielle Hijmans, Karin Beelen, Sabine C. Linn, Ana Maria Gonzalez-Angulo, Katherine Stemke-Hale, Michael Hauptmann, Roderick L. Beijersbergen, Gordon B. Mills, Marc J. van de Vijver, René Bernards, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. ,vol. 12, pp. 395- 402 ,(2007) , 10.1016/J.CCR.2007.08.030

José Baselga, Sunil Verma, Jungsil Ro, Jens Huober, Ellie Guardino, Liang Fang, Steven Olsen, Gail Lewis Phillips, Sanne de Haas, Mark Pegram, Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC). Cancer Research. ,vol. 73, ,(2013) , 10.1158/1538-7445.AM2013-LB-63

S Loibl, C Denkert, A Schneeweis, S Paepke, A Lehmann, M Rezai, D-M Zahm, P Sinn, F Khandan, H Eidtmann, K Dohnal, J Huober, S Loi, B Pfitzner, PA Fasching, F Andre, J Lindner, C Sotiriou, S Guo, S Gade, V Nekljudova, M Untch, G von Minckwitz, Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies Cancer Research. ,vol. 73, ,(2013) , 10.1158/0008-5472.SABCS13-S4-06

Yoichi Nagata, Keng-Hsueh Lan, Xiaoyan Zhou, Ming Tan, Francisco J. Esteva, Aysegul A. Sahin, Kristine S. Klos, Ping Li, Brett P. Monia, Nina T. Nguyen, Gabriel N. Hortobagyi, Mien-Chie Hung, Dihua Yu, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell. ,vol. 6, pp. 117- 127 ,(2004) , 10.1016/J.CCR.2004.06.022

Magdalena Cizkova, Aurélie Susini, Sophie Vacher, Géraldine Cizeron-Clairac, Catherine Andrieu, Keltouma Driouch, Emmanuelle Fourme, Rosette Lidereau, Ivan Bièche, PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups Breast Cancer Research. ,vol. 14, pp. 1- 9 ,(2012) , 10.1186/BCR3113

Dejan Juric, Jordi Rodon, Ana M. Gonzalez-Angulo, Howard A. Burris, Johanna Bendell, Jordan D. Berlin, Mark R. Middleton, Douglas Bootle, Markus Boehm, Antonin Schmitt, Nicolas Rouyrre, Cornelia Quadt, Jose Baselga, Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study Cancer Research. ,vol. 72, ,(2012) , 10.1158/1538-7445.AM2012-CT-01

Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M Swain, Tatiana Prowell, Sibylle Loibl, D Lawrence Wickerham, Jan Bogaerts, Jose Baselga, Charles Perou, Gideon Blumenthal, Jens Blohmer, Eleftherios P Mamounas, Jonas Bergh, Vladimir Semiglazov, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, Wolfgang Eiermann, Gunter Von Minckwitz, None, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis The Lancet. ,vol. 384, pp. 164- 172 ,(2014) , 10.1016/S0140-6736(13)62422-8